BioSante signs licensing deal

LINCOLNSHIRE -- BioSante Pharmaceuticals Inc. on Monday announced it has signed a license agreement covering the use of BioSante's calcium phosphate nanotechnology as a facial filler in aesthetic medicine.

The license was signed with Medical Aesthetics Technology Corp. Under the agreement, Medical Aesthetics is responsible for continued development of BioLook, including required clinical trials, regulatory filings and all manufacturing and marketing. In exchange for this license, BioSante has taken a 5.5 percent ownership position in the company.